Stage IIIA Breast Cancer Clinical Trial
Official title:
Virtual Weight Loss Program for African-American Breast Cancer Survivors
Verified date | April 2021 |
Source | Rutgers, The State University of New Jersey |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized pilot clinical trial studies how well a virtual weight loss program (SparkPeople) works in helping female African American breast cancer survivors maintain a healthy weight. Many patients with breast cancer are overweight or gain weight after diagnosis. SparkPeople is a free web-based weight loss program that features educational and motivational articles and videos, self-monitoring tools, incentives, social support communities (including discussion forums, teams, challenges, and expert blogs), and options for content to be delivered to members' email. It is a comprehensive program that includes advice on diet, physical activity, and behavioral strategies (such as self-monitoring diet and exercise), and emphasizes safe weight loss and receiving medical attention regularly when needed. A web-based program such as SparkPeople may help breast cancer survivors maintain a healthy weight, which may reduce the risk of cancer returning and patient fatigue, and improve patient quality of life.
Status | Completed |
Enrollment | 35 |
Est. completion date | July 29, 2018 |
Est. primary completion date | July 20, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 21 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients must have evidence of histologically confirmed breast cancer, stage 0, I, II or III, and be at least 2 years post diagnosis - Patient is self-identified as African-American - Patient is overweight or obese (body mass index [BMI] >= 25 kg/m^2) - Patient is able to understand and read English - Patient must have home internet or smartphone access - Patient must give informed consent for this new study Exclusion Criteria: - Patient has a serious medical condition (e.g., stroke, liver or renal failure, congestive heart failure, myocardial infarction or cardiac surgery in past year, angina pectoris) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator - Patient has serious psychiatric condition (e.g., bipolar disorder, schizophrenia or other psychosis, bulimia or anorexia nervosa, suicide attempt within 6 months or current active suicidal ideation) that would compromise the patient's ability to complete the study, at the discretion of the investigator - Patient has severe disabilities limiting moderate physical activity, such as severe orthopedic conditions - Patient is planning major surgery within the next 6 months - Patient is taking medications or supplements for weight loss currently or within the past 3 months - Patient has successfully lost 5% of body weight in the previous 6 months or has had bariatric surgery - Patient is pregnant, breastfeeding, has given birth within the last 3 months or planning pregnancy within the next 12 months; if participant becomes pregnant during the course of the study, she will be removed from further participation - Patient is anticipating leaving the area within the next 12 months |
Country | Name | City | State |
---|---|---|---|
United States | Rutgers Robert Wood Johnson Medical School | New Brunswick | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Rutgers, The State University of New Jersey | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment Rate | Number of eligible participants who were enrolled and randomly assigned. Feasibility is defined as >= 75% recruitment rate. | 12 months | |
Primary | Retention Rate | Number of participants completing study. Feasibility will be defined as >= 80% retention rate. | 6 months | |
Primary | Adherence to SparkPeople- Logged in | average number of days logged per week in to SparkPeople website | 0-3 months after intervention | |
Primary | Adherence to SparkPeople- Logged in | Average number of days per week logged in to SparkPeople website | 4-6 months after intervention | |
Primary | Adherence to SparkPeople- Logged Food | Average number of days per week logged food into SparkPeople | 0-3 months after intervention | |
Primary | Adherence to SparkPeople- Logged Food | Average number of days per week logged food into SparkPeople | 4-6 months after intervention | |
Primary | Acceptability of SparkPeople | Usefulness of SparkPeople website on 1 (not useful at all) to 4 (very useful) scale | 0-3 months after intervention | |
Primary | Acceptability of SparkPeople | Usefulness of SparkPeople website on 1 (not useful at all) to 4 (very useful) scale | 4-6 months after intervention | |
Primary | Adherence to Fitbit | average days used Fitbit per week | 0-3 months after intervention | |
Primary | Adherence to Fitbit | average days used Fitbit per week | 4-6 months after intervention | |
Primary | Acceptability of Fitbit | Usefulness of Fitbit, rated on 1 (not useful at all) to 4 (very useful) scale | 0-3 months after intervention | |
Primary | Acceptability of Fitbit | Usefulness of Fitbit, rated on 1 (not useful at all) to 4 (very useful) scale | 4-6 months after intervention | |
Secondary | Change in Weight | Change in weight from baseline | baseline and 3 months | |
Secondary | Change in Weight | Change in weight from baseline | baseline and 6 months | |
Secondary | Change in Waist Circumference | Change in waist circumference from baseline | baseline and 3 months | |
Secondary | Change in Waist Circumference | Change in waist circumference from baseline | baseline and 6 months | |
Secondary | Change in Caloric Intake | Changes in caloric intake per day, measured by 24-hour recall | baseline and 3 months | |
Secondary | Change in Caloric Intake | Changes in caloric intake per day, measured by 24-hour recall | baseline and 6 months | |
Secondary | Change in Physical Activity | change in average number of steps per day measured using Fitbit monitor | baseline and 3 months | |
Secondary | Change in Physical Activity | change in average number of steps per day measured using Fitbit monitor | baseline and 6 months | |
Secondary | Cardiopulmonary Fitness | change in fitness, measured by the 6-minute walk test | baseline and 3 months | |
Secondary | Cardiopulmonary Fitness | change in fitness, measured by the 6-minute walk test | baseline and 6 months | |
Secondary | Change in Quality of Life | measured using Quality of Life in Adult Cancer Survivors Scale (minimum 65, maximum 257); higher scores mean worse quality of life | baseline and 3 months | |
Secondary | Change in Quality of Life | measured using Quality of Life in Adult Cancer Survivors Scale (minimum 65, maximum 257); higher scores mean worse quality of life | baseline and 6 months | |
Secondary | Self-efficacy, Eating Healthy Foods | change in self-efficacy, eating healthy foods, measured with Health Beliefs Survey, scale range 0 (certain I cannot) to 100 (certain I can) | baseline and 3 months | |
Secondary | Self-efficacy, Eating Healthy Foods | change in self-efficacy, eating healthy foods, measured with Health Beliefs Survey, scale range 0 (certain I cannot) to 100 (certain I can) | baseline and 6 months | |
Secondary | Social Support for Healthy Nutrition | change in social support for healthy nutrition, measured by Health Beliefs Survey, scale range 1 (strongly disagree) to 5 (strongly agree); a higher number, e.g., 5 (strongly agree) is the more favorable outcome | baseline and 3 months | |
Secondary | Social Support for Healthy Nutrition | change in social support for healthy nutrition, measured by Health Beliefs Survey, scale range 1 (strongly disagree) to 5 (strongly agree); a higher number, e.g., 5 (strongly agree) is the more favorable outcome | baseline and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235051 -
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
|
N/A | |
Terminated |
NCT02454777 -
High-Intensity Interval Training for Stage I-III Breast Cancer Patients
|
N/A | |
Completed |
NCT03061175 -
Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
|
N/A | |
Completed |
NCT01959490 -
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03156309 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Completed |
NCT01928186 -
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
|
N/A | |
Terminated |
NCT01368263 -
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
|
Phase 2 | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00070252 -
Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02780401 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
Completed |
NCT01478477 -
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole
|
N/A | |
Completed |
NCT03364348 -
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
|
Phase 1 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01695057 -
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
|
N/A | |
Completed |
NCT01672684 -
Phase I: At-Home Support for Rural Women Using Group Video Calling
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01234532 -
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT00416715 -
Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
|
Phase 2 |